Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2025-08-21 Regulatory Filings
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease
Regulatory Filings Classification · 100% confidence The document is a corporate press release announcing that VeonGen Therapeutics has received FDA RMAT designation for its VG801 gene therapy. It provides details on the clinical significance of the designation, the company's pipeline, and contact information. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing of a specific legal nature. As it is a general corporate news announcement disseminated via a news service (EQS), it falls under the fallback category of Regulatory Filings (RNS).
2025-08-21 English
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Report Publication Announcement Classification · 99% confidence The document is a press release dated June 27, 2025, announcing that Vivoryon Therapeutics N.V.'s management will present at two upcoming investor conferences (mwb online Health Care Conference and H.C. Wainwright 4th Annual Kidney Virtual Conference) in July 2025. This type of announcement, which details future investor events, presentations, and roadshows, is best classified as an Investor Presentation (IP) announcement or, more broadly, a general regulatory/investor relations communication. Since the document itself is an announcement about future presentations rather than the presentation material itself, and it doesn't fit the specific definitions for ER, DIV, or CAP, it aligns closely with materials intended for investors regarding company activities. Given the options, 'Investor Presentation' (IP) is the most fitting category for an announcement detailing management's schedule for presenting company updates at investor conferences. It is not a full report (10-K, IR), a transcript (CT), or a specific financial event notice (DIV, ER).
2025-06-27 English
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial results announcement for Vivoryon Therapeutics N.V. for the period ended March 31, 2025. It contains substantive financial data (revenues, R&D expenses, G&A expenses, net loss, and cash position) and management's discussion of operational progress. While it mentions an upcoming conference call, it is not a transcript (CT) nor a mere announcement of a report (RPA), as it provides the actual financial figures and analysis for the quarter. Therefore, it is classified as an Interim/Quarterly Report. Q1 2025
2025-06-17 English
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
Report Publication Announcement Classification · 98% confidence The document is a press release announcing that Vivoryon Therapeutics N.V. will publish its Q1 2025 financial results and host a conference call on June 17, 2025. It explicitly states the date and time for the release of the financial results and the associated call details. This type of announcement, which precedes the actual release of detailed financial statements (like an ER or IR), is best classified as a Report Publication Announcement (RPA), as it informs stakeholders about *when* a report will be published, rather than being the report itself. The document length (4928 chars) is short, supporting the RPA classification over a full Earnings Release (ER) or Interim Report (IR).
2025-06-11 English
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Regulatory Filings Classification · 92% confidence The document is a press release dated June 6, 2025, announcing that Vivoryon Therapeutics presented meta-analysis data from its VIVIAD and VIVA-MIND studies at the ERA 2025 congress. It details the presentation highlights, presentation logistics (date, time, venue), and includes standard company boilerplate and contact information. This format—a news announcement about scientific data presentation or clinical trial updates—is characteristic of an Investor Presentation (IP) or a general press release that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a detailed announcement focusing on clinical data and future development plans aimed at investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release. Given the options, it is not a formal regulatory filing like 10-K or a standalone Audit Report (AR). It is an announcement of scientific findings, which often accompanies or precedes a formal Investor Presentation, but the content itself is a detailed update. If the document were the actual slide deck, it would be IP. As a detailed press release summarizing scientific findings and future steps, it aligns closely with the informational depth expected in an IP, but since it's a news release format, 'Regulatory Filings' (RNS) is often used for non-standard announcements. However, the content is highly specific to investor/scientific communication regarding drug development, making 'IP' a strong candidate if the content is considered the substance of the presentation summary. Given the context of financial reporting databases, detailed scientific updates like this are often grouped with Investor Presentations (IP) or sometimes Earnings Releases (ER) if they coincide with reporting periods. Since this is purely scientific data presentation news, and not a formal financial report or a simple announcement of a report release (RPA), I will classify it as an Investor Presentation (IP) as it conveys the core information that would be in the presentation slides, or RNS as a general announcement. Given the depth of the scientific detail, IP is slightly better than the generic RNS fallback, but RNS is safer for press releases not explicitly defined elsewhere. Let's re-evaluate: It is a press release announcing data presented at a conference. This is a common type of corporate communication. It is not a 10-K, ER, IR, or AR. It is not a simple RPA. It is a specific scientific update. In many databases, such scientific updates are classified under RNS (Regulatory Filings/Announcements) if they don't fit a specific financial report type. I will use RNS as the most appropriate general announcement category for non-standard, non-financial report press releases.
2025-06-06 English
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
Regulatory Filings Classification · 100% confidence The document is a press release dated June 5, 2025, announcing a corporate rebranding (ViGeneron to VeonGen Therapeutics) and significant clinical/regulatory updates, specifically receiving FDA Rare Pediatric Disease Designation for VG801 and progress in a Phase 1/2 trial. It contains key highlights, company background, and contact information, typical of an initial public announcement of material, non-financial news. Since it is a general corporate announcement detailing strategic and clinical progress rather than a formal financial report (like 10-K, IR, or ER), it fits best under the general Regulatory Filings category (RNS) as a broad corporate news release disseminated via EQS News, which explicitly mentions handling 'Corporate News' and 'Press Releases'. It is not a specific financial filing, management change, or dividend notice.
2025-06-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.